Form 4: Denali COFO Sells Shares for Tax Obligations
Insider Transaction Report
Denali Therapeutics' COFO and Secretary, Alexander O. Schuth, sold 2,937 shares of common stock to cover tax obligations related to vested restricted stock units.
Summary
- Alexander O. Schuth, COFO and Secretary of Denali Therapeutics Inc. (DNLI), sold 2,937 shares of common stock.
- The sale occurred on August 12, 2025, at a weighted average price of $13.58 per share.
- The purpose of the sale was to satisfy tax obligations arising from the settlement of previously vested restricted stock units.
- Following the transaction, Schuth directly owns 242,346 shares, which includes 128,405 unvested RSUs and 975 shares acquired via ESPP on June 2, 2025.
- Schuth also indirectly owns 523,749 shares through The Schuth Family Trust U/A DTD 06/05/2017, for which he serves as trustee.
Sentiment
Score: 5
Explanation: A Form 4 reporting a 'sell to cover' transaction is a routine event for executives and generally has a neutral impact on company sentiment. It indicates vested compensation, but the sale itself is for personal tax purposes, not necessarily a reflection of management's view on the company's future.
Positives
- Vesting of restricted stock units indicates successful achievement of prior performance milestones or tenure, leading to compensation for the executive.
Negatives
- Sale of shares by an insider, even for tax purposes, reduces their direct equity stake in the company.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: Minor dilution effect from the sale, but primarily a routine insider transaction for tax purposes.
Key Dates
| Date | Description |
|---|---|
| 06/05/2017 | Date of The Schuth Family Trust U/A DTD. |
| 06/02/2025 | Date of ESPP purchase of 975 shares. |
| 08/12/2025 | Date of common stock transaction (sale of shares). |
| 08/14/2025 | Date of Form 4 filing signature. |
Recommendation
holdThis Form 4 details a routine insider transaction where an executive sold shares to cover tax obligations related to vested restricted stock units. Such transactions are common and do not typically signal a change in the company's fundamental outlook or performance. Therefore, it does not provide a basis for a 'buy' or 'sell' recommendation, suggesting a 'hold' position is appropriate as this filing does not alter the investment thesis.
Keywords
Denali Therapeutics, DNLI, Alexander O. Schuth, Insider Trading, Form 4, Stock Sale, Restricted Stock Units, RSU, Tax Obligations, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.